NBIX
Neurocrine Biosciences, Inc.
Price Chart
Latest Quote
$171.55
-0.50 (-0.29%)
Current Price
| Previous Close | $172.05 |
| Open | $170.78 |
| Day High | $172.62 |
| Day Low | $169.01 |
| Volume | 885,424 |
Stock Information
| Shares Outstanding | 100.55M |
| Total Debt | $463.50M |
| Cash Equivalents | $1.32B |
| Revenue | $3.10B |
| Net Income | $668.60M |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Market Cap | $17.18B |
| P/E Ratio | 26.37 |
| EPS (TTM) | $6.48 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $16.33B |
| Sales | $3.10B |
| Income | $668.60M |
| Book/sh | $33.87 |
| Cash/sh | $13.09 |
| Employees | 2K |
Financial Ratios
| Quick Ratio | 2.51 |
| Current Ratio | 2.93 |
| Debt/Eq | 13.60 |
| EPS Growth TTM | 2405.10% |
Returns & Margins
| ROA | 11.62% |
| ROE | 22.50% |
| Gross Margin | 64.37% |
| Operating Margin | 22.84% |
| Profit Margin | 21.55% |
Ownership
| Insider Ownership | 1.08% |
| Institutional Ownership | 104.21% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 13.62 |
| PEG | 0.49 |
| P/S | 5.54 |
| P/B | 5.05 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $199.27 |
Technical Indicators
| SMA20 | $170.44 |
| SMA50 | $162.93 |
| SMA200 | $143.97 |
| RSI | 54.45 |
| ATR | 4.5164 |
| Shares Float | 99.30M |
| Short Float | 7.17% |
| Short Ratio | 4.48 |
| Volatility | 0.39 |
| Rel Volume | 0.77 |
Performance History
| Week | -3.52% |
| Month | +9.24% |
| Quarter | +33.07% |
| 6 Months | +26.27% |
| YTD | +21.54% |
| Year | +28.02% |
| 3 Years | +75.75% |
| 5 Years | +72.55% |
| 10 Years | +263.81% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-07-17 | $170.88 | 929,700 |
| 2026-07-16 | $171.55 | 900,800 |
| 2026-07-15 | $172.05 | 878,300 |
| 2026-07-14 | $172.04 | 1,054,000 |
| 2026-07-13 | $174.10 | 1,573,000 |
| 2026-07-10 | $177.11 | 1,047,400 |
| 2026-07-09 | $180.55 | 1,178,600 |
| 2026-07-08 | $178.24 | 1,155,600 |
| 2026-07-07 | $177.49 | 1,033,800 |
| 2026-07-06 | $174.10 | 922,900 |
| 2026-07-02 | $174.26 | 1,251,000 |
| 2026-07-01 | $167.77 | 927,300 |
| 2026-06-30 | $168.54 | 1,075,600 |
| 2026-06-29 | $170.00 | 1,350,700 |
| 2026-06-26 | $168.52 | 1,953,000 |
| 2026-06-25 | $164.18 | 783,700 |
| 2026-06-24 | $166.06 | 1,362,000 |
| 2026-06-23 | $161.44 | 1,076,100 |
| 2026-06-22 | $161.62 | 1,008,800 |
| 2026-06-18 | $158.29 | 2,718,000 |
About Neurocrine Biosciences, Inc.
Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and Efmody. Its product candidates in clinical development includes NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia and bipolar mania; NBI-1117567 for the treatment of Alzheimer's disease; NBI 921355 for the treatment of epilepsy; NBIP-01435 for the treatment of congenital adrenal hyperplasia; NBIP-2118 for the treatment of obesity and related metabolic diseases; and NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, NBI-1140675, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Sanofi S.A.; Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.
đ° Latest News
Profitable Biotechs Strut Their Stuff As Stock Market Stumbles
Investor's Business Daily âĸ 2026-07-17T17:38:07Z
Here's Why You Should Add INKT Stock to Your Portfolio Now
Zacks âĸ 2026-07-16T16:24:00Z
Zacks.com featured highlights include NVIDIA, Neurocrine Biosciences and Ball
Zacks âĸ 2026-07-16T07:47:00Z
NVIDIA & 2 Best Earnings Growth Stocks to Buy for 2H 2026
Zacks âĸ 2026-07-15T19:00:00Z
Summit to Divest Late-Stage Antibiotic Drug to Biossil in $105M Deal
Zacks âĸ 2026-07-15T12:48:00Z
Can Neurocrine (NBIX) Run Higher on Rising Earnings Estimates?
Zacks âĸ 2026-07-14T16:20:02Z
CG Oncology Stock Gains 12% in Three Months: What's Driving It?
Zacks âĸ 2026-07-13T13:03:00Z
3 Reasons Why Growth Investors Shouldn't Overlook Neurocrine (NBIX)
Zacks âĸ 2026-07-10T16:45:02Z
Neurocrine Shares Hit Highs on Sales Spike, Strong Pipeline
FX Empire âĸ 2026-07-10T15:58:48Z
United Therapeutics Stock Rises 14% YTD: Here's What You Need to Know
Zacks âĸ 2026-07-09T18:26:00Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $52,100,000 | $34,000,000 | $39,700,000 | $23,200,000 |
| Cost Of Revenue | $52,100,000 | $34,000,000 | $39,700,000 | $23,200,000 |
| Total Revenue | $2,860,500,000 | $2,355,300,000 | $1,887,100,000 | $1,488,700,000 |
| Operating Revenue | $2,860,500,000 | $2,355,300,000 | $1,887,100,000 | $1,488,700,000 |
| Expenses | ||||
| Total Expenses | $2,224,000,000 | $1,772,300,000 | $1,492,300,000 | $1,239,700,000 |
| Other Income Expense | $-21,400,000 | $-61,400,000 | $-115,500,000 | $-39,200,000 |
| Net Non Operating Interest Income Expense | $90,300,000 | $-35,600,000 | $52,800,000 | $4,100,000 |
| Operating Expense | $2,171,900,000 | $1,738,300,000 | $1,452,600,000 | $1,216,500,000 |
| Interest Expense | - | $126,600,000 | $4,600,000 | $7,100,000 |
| Interest Expense Non Operating | - | $126,600,000 | $4,600,000 | $7,100,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $478,600,000 | $341,300,000 | $249,700,000 | $154,500,000 |
| Net Interest Income | $90,300,000 | $-35,600,000 | $52,800,000 | $4,100,000 |
| Interest Income | $90,300,000 | $91,000,000 | $52,800,000 | $4,100,000 |
| Normalized Income | $493,119,478 | $384,418,971 | $336,542,367 | $182,814,165 |
| Net Income From Continuing And Discontinued Operation | $478,600,000 | $341,300,000 | $249,700,000 | $154,500,000 |
| Total Operating Income As Reported | $619,100,000 | $570,500,000 | $250,900,000 | $249,000,000 |
| Net Income Common Stockholders | $478,600,000 | $341,300,000 | $249,700,000 | $154,500,000 |
| Net Income | $478,600,000 | $341,300,000 | $249,700,000 | $154,500,000 |
| Net Income Including Noncontrolling Interests | $478,600,000 | $341,300,000 | $249,700,000 | $154,500,000 |
| Net Income Continuous Operations | $478,600,000 | $341,300,000 | $249,700,000 | $154,500,000 |
| Pretax Income | $705,400,000 | $486,000,000 | $332,100,000 | $213,900,000 |
| Special Income Charges | $-17,400,000 | $-14,700,000 | $-143,900,000 | $-70,000,000 |
| Interest Income Non Operating | $90,300,000 | $91,000,000 | $52,800,000 | $4,100,000 |
| Operating Income | $636,500,000 | $583,000,000 | $394,800,000 | $249,000,000 |
| Gross Profit | $2,808,400,000 | $2,321,300,000 | $1,847,400,000 | $1,465,500,000 |
| Per Share | ||||
| Diluted EPS | $4.67 | $3.29 | $2.47 | $1.56 |
| Basic EPS | $4.81 | $3.40 | $2.56 | $1.61 |
| Other | ||||
| Tax Effect Of Unusual Items | $-6,880,522 | $-18,281,029 | $-28,657,633 | $-10,885,835 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $688,000,000 | $701,100,000 | $531,600,000 | $303,800,000 |
| Total Unusual Items | $-21,400,000 | $-61,400,000 | $-115,500,000 | $-39,200,000 |
| Total Unusual Items Excluding Goodwill | $-21,400,000 | $-61,400,000 | $-115,500,000 | $-39,200,000 |
| Reconciled Depreciation | $30,100,000 | $27,100,000 | $21,300,000 | $15,600,000 |
| EBITDA (Bullshit earnings) | $666,600,000 | $639,700,000 | $416,100,000 | $264,600,000 |
| EBIT | $636,500,000 | $612,600,000 | $394,800,000 | $249,000,000 |
| Diluted Average Shares | $102,500,000 | $103,700,000 | $101,000,000 | $98,900,000 |
| Basic Average Shares | $99,500,000 | $100,400,000 | $97,700,000 | $95,800,000 |
| Diluted NI Availto Com Stockholders | $478,600,000 | $341,300,000 | $249,700,000 | $154,500,000 |
| Tax Provision | $226,800,000 | $144,700,000 | $82,400,000 | $59,400,000 |
| Other Special Charges | $17,400,000 | $14,700,000 | $143,900,000 | $70,000,000 |
| Gain On Sale Of Security | $-4,000,000 | $-46,700,000 | $28,400,000 | $30,800,000 |
| Research And Development | $1,015,700,000 | $731,100,000 | $565,000,000 | $463,800,000 |
| Selling General And Administration | $1,156,200,000 | $1,007,200,000 | $887,600,000 | $752,700,000 |
Fetched: 2026-07-15
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $3,253,100,000 | $2,589,700,000 | $2,196,500,000 | $1,670,600,000 |
| Total Assets | $4,631,500,000 | $3,718,700,000 | $3,251,400,000 | $2,368,700,000 |
| Total Non Current Assets | $2,108,800,000 | $1,994,000,000 | $1,644,400,000 | $915,200,000 |
| Other Non Current Assets | $59,500,000 | $52,000,000 | $49,600,000 | $25,000,000 |
| Non Current Deferred Assets | $320,300,000 | $485,700,000 | $362,600,000 | $305,900,000 |
| Non Current Deferred Taxes Assets | $320,300,000 | $485,700,000 | $362,600,000 | $305,900,000 |
| Investmentin Financial Assets | $1,183,800,000 | $864,300,000 | $849,400,000 | $401,500,000 |
| Current Assets | $2,522,700,000 | $1,724,700,000 | $1,607,000,000 | $1,453,500,000 |
| Other Current Assets | $115,800,000 | $63,600,000 | $97,800,000 | $79,100,000 |
| Prepaid Assets | $170,700,000 | $48,500,000 | - | - |
| Inventory | $69,000,000 | $57,400,000 | $38,300,000 | $35,100,000 |
| Receivables | $686,800,000 | $479,100,000 | $439,300,000 | $350,000,000 |
| Accounts Receivable | $686,800,000 | $479,100,000 | $439,300,000 | $350,000,000 |
| Cash Cash Equivalents And Short Term Investments | $1,480,400,000 | $1,076,100,000 | $1,031,600,000 | $989,300,000 |
| Cash And Cash Equivalents | $713,000,000 | $233,000,000 | $251,100,000 | $262,900,000 |
| Goodwill And Other Intangible Assets | - | $36,500,000 | $35,500,000 | $37,200,000 |
| Other Intangible Assets | - | $36,500,000 | $35,500,000 | $37,200,000 |
| Debt | ||||
| Total Debt | $415,300,000 | $455,100,000 | $428,400,000 | $262,900,000 |
| Long Term Debt And Capital Lease Obligation | $415,300,000 | $455,100,000 | $258,300,000 | $93,500,000 |
| Current Debt And Capital Lease Obligation | - | - | $170,100,000 | $169,400,000 |
| Current Debt | - | - | $170,100,000 | $169,400,000 |
| Other Current Borrowings | - | - | $170,100,000 | $169,400,000 |
| Long Term Debt | - | - | - | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $1,378,400,000 | $1,129,000,000 | $1,019,400,000 | $660,900,000 |
| Total Non Current Liabilities Net Minority Interest | $635,000,000 | $621,300,000 | $364,600,000 | $123,200,000 |
| Other Non Current Liabilities | $5,200,000 | $5,500,000 | $10,300,000 | $9,900,000 |
| Tradeand Other Payables Non Current | $214,500,000 | $160,700,000 | $96,000,000 | $19,800,000 |
| Current Liabilities | $743,400,000 | $507,700,000 | $654,800,000 | $537,700,000 |
| Other Current Liabilities | $69,100,000 | $46,100,000 | $35,900,000 | $20,700,000 |
| Payables And Accrued Expenses | $319,500,000 | $209,900,000 | $223,300,000 | $142,900,000 |
| Payables | $172,900,000 | $109,900,000 | $133,300,000 | $76,300,000 |
| Total Tax Payable | $68,000,000 | $10,000,000 | $24,400,000 | $9,000,000 |
| Income Tax Payable | $68,000,000 | $10,000,000 | $24,400,000 | $9,000,000 |
| Accounts Payable | $104,900,000 | $99,900,000 | $133,300,000 | $67,300,000 |
| Equity | ||||
| Common Stock Equity | $3,253,100,000 | $2,589,700,000 | $2,232,000,000 | $1,707,800,000 |
| Total Equity Gross Minority Interest | $3,253,100,000 | $2,589,700,000 | $2,232,000,000 | $1,707,800,000 |
| Stockholders Equity | $3,253,100,000 | $2,589,700,000 | $2,232,000,000 | $1,707,800,000 |
| Gains Losses Not Affecting Retained Earnings | $13,100,000 | $5,800,000 | $7,000,000 | $-7,900,000 |
| Other Equity Adjustments | $13,100,000 | $5,800,000 | $7,000,000 | $-7,900,000 |
| Retained Earnings | $447,700,000 | $29,200,000 | $-157,100,000 | $-406,800,000 |
| Other | ||||
| Ordinary Shares Number | $100,100,000 | $99,400,000 | $98,700,000 | $96,500,000 |
| Share Issued | $100,100,000 | $99,400,000 | $98,700,000 | $96,500,000 |
| Tangible Book Value | $3,253,100,000 | $2,589,700,000 | $2,196,500,000 | $1,670,600,000 |
| Invested Capital | $3,253,100,000 | $2,589,700,000 | $2,402,100,000 | $1,877,200,000 |
| Working Capital | $1,779,300,000 | $1,217,000,000 | $952,200,000 | $915,800,000 |
| Capital Lease Obligations | $415,300,000 | $455,100,000 | $258,300,000 | $93,500,000 |
| Total Capitalization | $3,253,100,000 | $2,589,700,000 | $2,232,000,000 | $1,707,800,000 |
| Additional Paid In Capital | $2,792,200,000 | $2,554,600,000 | $2,382,000,000 | $2,122,400,000 |
| Capital Stock | $100,000 | $100,000 | $100,000 | $100,000 |
| Common Stock | $100,000 | $100,000 | $100,000 | $100,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $415,300,000 | $455,100,000 | $258,300,000 | $93,500,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $128,800,000 | $107,500,000 | $86,200,000 | $72,800,000 |
| Current Provisions | $226,000,000 | $144,200,000 | $139,300,000 | $131,900,000 |
| Current Accrued Expenses | $146,600,000 | $100,000,000 | $90,000,000 | $66,600,000 |
| Investments And Advances | $1,183,800,000 | $864,300,000 | $849,400,000 | $401,500,000 |
| Available For Sale Securities | $1,183,800,000 | $864,300,000 | $849,400,000 | $401,500,000 |
| Net PPE | $545,200,000 | $592,000,000 | $347,300,000 | $145,600,000 |
| Accumulated Depreciation | $-118,300,000 | $-106,500,000 | $-83,000,000 | $-66,300,000 |
| Gross PPE | $663,500,000 | $698,500,000 | $430,300,000 | $211,900,000 |
| Leases | $35,600,000 | $35,900,000 | $38,100,000 | $37,900,000 |
| Other Properties | $578,700,000 | $605,100,000 | $356,100,000 | $145,800,000 |
| Machinery Furniture Equipment | $49,200,000 | $57,500,000 | $36,100,000 | $28,200,000 |
| Properties | $0 | $0 | $0 | $0 |
| Inventories Adjustments Allowances | $-200,000 | $0 | $-5,200,000 | $0 |
| Finished Goods | $14,300,000 | $12,800,000 | $12,300,000 | $17,500,000 |
| Work In Process | $19,200,000 | $10,900,000 | $9,700,000 | $5,600,000 |
| Raw Materials | $35,700,000 | $33,700,000 | $21,500,000 | $12,000,000 |
| Other Short Term Investments | $767,400,000 | $843,100,000 | $780,500,000 | $726,400,000 |
Fetched: 2026-07-15
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $748,700,000 | $557,200,000 | $361,600,000 | $322,900,000 |
| Operating Activities | ||||
| Operating Cash Flow | $782,700,000 | $595,400,000 | $389,900,000 | $339,400,000 |
| Cash Flow From Continuing Operating Activities | $782,700,000 | $595,400,000 | $389,900,000 | $339,400,000 |
| Operating Gains Losses | - | - | - | $70,000,000 |
| Investing Activities | ||||
| Capital Expenditure | $-34,000,000 | $-38,200,000 | $-28,300,000 | $-16,500,000 |
| Investing Cash Flow | $-264,400,000 | $-126,800,000 | $-467,100,000 | $-177,100,000 |
| Cash Flow From Continuing Investing Activities | $-264,400,000 | $-126,800,000 | $-467,100,000 | $-177,100,000 |
| Capital Expenditure Reported | $-34,000,000 | $-38,200,000 | $-28,300,000 | $-16,500,000 |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $-167,700,000 | $-300,000,000 | $0 | $0 |
| Financing Cash Flow | $-38,300,000 | $-486,700,000 | $65,300,000 | $-234,300,000 |
| Cash Flow From Continuing Financing Activities | $-38,300,000 | $-486,700,000 | $65,300,000 | $-234,300,000 |
| Net Common Stock Issuance | $-167,700,000 | $-300,000,000 | $0 | $0 |
| Other | ||||
| Repayment Of Debt | $0 | $-308,800,000 | $0 | $-279,000,000 |
| Interest Paid Supplemental Data | $0 | $1,600,000 | $3,800,000 | $6,600,000 |
| Income Tax Paid Supplemental Data | $81,400,000 | $217,500,000 | $51,500,000 | $14,400,000 |
| End Cash Position | $721,000,000 | $241,000,000 | $259,100,000 | $270,700,000 |
| Beginning Cash Position | $241,000,000 | $259,100,000 | $270,700,000 | $344,000,000 |
| Effect Of Exchange Rate Changes | $0 | $0 | $300,000 | $-1,300,000 |
| Changes In Cash | $480,000,000 | $-18,100,000 | $-11,900,000 | $-72,000,000 |
| Proceeds From Stock Option Exercised | $129,400,000 | $122,100,000 | $65,300,000 | $44,700,000 |
| Common Stock Payments | $-167,700,000 | $-300,000,000 | $0 | $0 |
| Net Issuance Payments Of Debt | $0 | $-308,800,000 | $0 | $-279,000,000 |
| Net Long Term Debt Issuance | $0 | $-308,800,000 | $0 | $-279,000,000 |
| Long Term Debt Payments | $0 | $-308,800,000 | $0 | $-279,000,000 |
| Net Investment Purchase And Sale | $-230,400,000 | $-88,600,000 | $-438,800,000 | $-117,900,000 |
| Sale Of Investment | $1,089,400,000 | $967,500,000 | $972,400,000 | $511,000,000 |
| Purchase Of Investment | $-1,319,800,000 | $-1,056,100,000 | $-1,411,200,000 | $-628,900,000 |
| Change In Working Capital | $-128,800,000 | $-19,200,000 | $28,200,000 | $-67,400,000 |
| Change In Other Working Capital | $-63,200,000 | $-3,700,000 | $63,100,000 | $-17,200,000 |
| Change In Payables And Accrued Expense | $160,200,000 | $43,400,000 | $49,000,000 | $114,600,000 |
| Change In Inventory | $-15,300,000 | $-19,100,000 | $5,400,000 | $-2,600,000 |
| Change In Receivables | $-210,500,000 | $-39,800,000 | $-89,300,000 | $-162,200,000 |
| Changes In Account Receivables | $-210,500,000 | $-39,800,000 | $-89,300,000 | $-162,200,000 |
| Other Non Cash Items | $14,800,000 | $122,700,000 | $-18,500,000 | $71,600,000 |
| Stock Based Compensation | $217,900,000 | $195,500,000 | $194,300,000 | $173,100,000 |
| Unrealized Gain Loss On Investment Securities | $4,000,000 | $37,100,000 | $-28,400,000 | $-30,800,000 |
| Asset Impairment Charge | $700,000 | $14,000,000 | $0 | - |
| Deferred Tax | $165,400,000 | $-123,100,000 | $-56,700,000 | $19,100,000 |
| Deferred Income Tax | $165,400,000 | $-123,100,000 | $-56,700,000 | $19,100,000 |
| Depreciation Amortization Depletion | $30,100,000 | $27,100,000 | $21,300,000 | $15,600,000 |
| Depreciation And Amortization | $30,100,000 | $27,100,000 | $21,300,000 | $15,600,000 |
| Amortization Cash Flow | $4,100,000 | $3,600,000 | $3,500,000 | $500,000 |
| Amortization Of Intangibles | $4,100,000 | $3,600,000 | $3,500,000 | $500,000 |
| Depreciation | $26,000,000 | $23,500,000 | $17,800,000 | $15,100,000 |
| Net Income From Continuing Operations | $478,600,000 | $341,300,000 | $249,700,000 | $154,500,000 |
| Net Short Term Debt Issuance | - | $-308,800,000 | $0 | $-279,000,000 |
| Short Term Debt Payments | - | $-308,800,000 | $0 | $-279,000,000 |
| Net Business Purchase And Sale | - | $0 | $0 | $-42,700,000 |
| Purchase Of Business | - | $0 | $0 | $-42,700,000 |
| Amortization Of Securities | - | $-26,200,000 | $-18,300,000 | $3,700,000 |
| Net PPE Purchase And Sale | - | - | - | - |
| Purchase Of PPE | - | - | - | - |
Fetched: 2026-07-15